Psychopathology in multiple sclerosis: Diagnosis, prevalence and treatment

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 1, 2009, Pages 13-29

  Haussleiter, Ida S ^a   Brüne, Martin ^a   Juckel, Georg ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Coping; Multiple sclerosis; Outcome; Psychiatric comorbidity

Indexed keywords

4 AMINOPYRIDINE; ALPHA INTERFERON; AMANTADINE; AMITRIPTYLINE; ARIPIPRAZOLE; BETA INTERFERON; BETA1A INTERFERON; CLOZAPINE; CYCLOPHOSPHAMIDE; DESIPRAMINE; DEXTROMETHORPHAN; DONEPEZIL; ETIRACETAM; FLUOXETINE; GLATIRAMER; INTERLEUKIN 1; LEVODOPA; LITHIUM CARBONATE; METHYLPREDNISOLONE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PEMOLINE; PLACEBO; QUINIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; COPING BEHAVIOR; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; EUPHORIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; MALAISE; MANIA; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYALGIA; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PREVALENCE; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SUICIDE; UNSPECIFIED SIDE EFFECT;

EID: 76049125783     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608100325     Document Type: Review

References (140)

1. Aarsland, D. and Figved, N. (2007) Are anxiety disorders undertreated in patients with multiple sclerosis?, Nat Clin Pract Neurol 3: 372-373.
2. Aikens, J.E., Fischer, J.S., Namey, M. and Rudick, R.A. (1997) A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis, J Behav Med 5: 433-445.
3. Allen, D.D., Goldstein, G., Heyman, R.A. and Rondinelli, T. (1998) Teaching memory strategies to persons with multiple sclerosis, J Rehabil Res Dev 35: 405-410.
4. Amato, M.P., Portaccio, E. and Zipoli, V. (2006 a) Are there protective treatments for cognitive decline in MS?, J Neurol Sci 245: 183-186.
5. Amato, M.P., Zipoli, V., Goretti, B., Portaccio, E., de Caro, M.F., Ricchiuti, L. et al. (2006 b) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort, J Neurol 253: 1054-1059.
6. Amato, M.P., Zipoli, V. and Portaccio, E. (2006 c) Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies, J Neurol Sci 245: 41-46.
7. Ameis, S.H. and Feinsein, A. (2006) Treatment of neuropsychiatric conditions associated with multiple sclerosis, Expert Rev Neurother 6: 1555-1567.
8. Arciniegas, D.B. (2005) A clinical overview of pseudobulbar affect, Am J Geriatr Pharmacother 3 (Suppl. A): 4-8; quiz 16-17.
9. Arnett, P.A. and Randolph, J.J. (2006) Longitudinal course of depression symptoms in multiple sclerosis, J Neurol Neurosurg Psychiatry 77: 606-610.
10. Bakshi, R., Czarnecki, D., Shaikh, Z.A., Priore, R.L., Janardhan, V., Kaliszky, Z. et al. (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis, Neuroreport 11: 1153-1158.
11. Barak, Y. and Achiron, A. (2002) Effect of interferon-beta-1b on cognitive functions in multiple sclerosis, Eur Neurol 47: 11-14.
12. Beiske, A.G., Svensson, E., Sandanger, I., Czujko, B., Pedersen, E.D., Aarseth, J.H. et al. (2008) Depression and anxiety amongst multiple sclerosis patients, Eur J Neurol 15: 239-245.
13. Benedict, R.H. and Bobholz, J.H. (2007) Multiple sclerosis, Semin Neurol 27: 78-85.
14. Benedict, R.H., Cookfair, D., Gavett, R., Gunther, M., Munschauer, F., Garg, N. et al. (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS), J Int Neuropsychol Soc 12: 549-558.
15. Benedict, R.H., Zivadinov, R., Carone, D.A., Weinstock-Guttman, B., Gaines, J., Maggiore, C. et al. (2005) Regional lobar atrophy predicts memory impairment in multiple sclerosis, AJNR Am J Neuroradiol 26: 1824-1831.
16. Bermel, R.A. and Bakshi, R. (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis, Lancet Neurol 5: 158-170.
17. Bian, Q., Kato, T., Monji, A., Hashioka, S., Mizoguchi, Y., Horikawa, H. et al. (2008) The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma, Prog Neuropsychopharmacol Biol Psychiatry 32: 42-48.
18. Bobholz, J.A. and Rao, S.M. (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments, Curr Opin Neurol 16: 283-288.
19. Bobholz, J.A., Rao, S.M., Lobeck, L., Elsinger, C., Gleason, A., Kanz, J. et al. (2006) fMRI study of episodic memory in relapsing-remitting MS: correlation with T 2 lesion volume, Neurology 67: 1640-1645.
20. Calabrese, P. (2006) Neuropsychology of multiple sclerosis. An overview, J Neurol 253(Suppl. 1): 10-15.
21. Charcot, J.M. (1877) Lectures on the Diseases of the Nervous System. La Salpêtrière: London.
22. Chong, S. and Ko, S. (1997) Clozapine treatment of psychosis associated with multiple sclerosis, Can J Psychiat 42: 90-91.
23. Chwastiak, L., Ehde, D.M., Gibbons, L.E., Sullivan, M., Bowen, J.D. and Kraft, G.H. (2002) Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample, Am J Psychiatry 159: 1862-1868.
24. Cottrell, S.S. and Wilson, S.A.K. (1926) The affective symptomatology of disseminated sclerosis, J Neurol Psychopathol 7: 1-30.
25. Crayton, H.J. and Rossman, H.S. (2006) Managing the symptoms of multiple sclerosis: a multimodal approach, Clin Ther 28: 445-460.
26. Cuijpers, P. and Smit, F. (2002) Excess mortality in depression: a meta-analysis of community studies, J Affect Disord 72: 227-236.
27. Cummings, J.L., Arciniegas, D.B., Brooks, B.R., Herndon, R.M., Lauterbach, E.C., Pioro, E.P. et al. (2006) Defining and diagnosing involuntary emotional expression disorder, CNS Spectr 11: 1-7.
28. Davids, E., Hartwig, U. and Gastpar, M. (2004) Antipsychotic treatment of psychosis associated with multiple sclerosis, Prog Neuropsychopharmacol Biol Psychiatry 28: 743-744.
29. Diaz-Olavarrieta, C., Cummings, J.L., Velazquez, J. and Garcia de la Cadena, C. (1999) Neuropsychiatric manifestations of multiple sclerosis, J Neuropsychiatry Clin Neurosci 11: 51-57.
30. Dunn, A.J., Swiergiel, A.H. and de Beaurepaire, R. (2005) Cytokines as mediators of depression: what can we learn from animal studies?, Neurosci Biobehav Rev 29: 891-909.
31. Ebers, G.C. (2008) Environmental factors and multiple sclerosis, Lancet Neurol 7: 268-277.
32. Fassbender, K., Schmidt, R., Moßner, R., Kischka, U., Kuhnen, J., Schwartz, A. et al. (1998) Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis, Arch Neurol 55: 66-72.
33. Feinstein, A. (1999) The Clinical Neuropsychiatry of Multiple Sclerosis. Cambridge University Press: Cambridge.
34. Feinstein, A. (2002) An examination of suicidal intent in patients with multiple sclerosis, Neurology 59: 674-678.
35. Feinstein, A. (2004) The neuropsychiatry of multiple sclerosis, Can J Psychiatry 49: 157-163.
36. Feinstein, A., du Boulay, G. and Ron, M.A. (1992) Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study, Br J Psychiatry 161: 680-685.
37. Feinstein, A., Feinstein, K.J., Gray, T. and O'Connor, P. (1997) The prevalence and neurobehavioral correlates of pathological laughter and crying in multiple sclerosis, Arch Neurol 54: 1116-1121.
38. Feinstein, A., O'Connor, P. and Feinstein, K. (2002) Multiple sclerosis, interferon beta-1b and depression. A prospective investigation, J Neurol 249: 815-820.
39. Feinstein, A., Roy, P., Lobaugh, N., Feinstein, K., O'Connor, P. and Black, S. (2004) Structural brain abnormalities in multiple sclerosis patients with major depression, Neurology 62: 586-590.
40. Folkman, S. and Moskowitz, J.T. (2004) Coping: pitfalls and promise, Annu Rev Psychol 55: 745-774.
41. Foong, J. and Ron, M.A. (2003) ‘Neuropsychiatry: cognition and mood disorders’. In McDonald, W.I. and Noseworthy, J.H. (eds) Multiple Sclerosis 2. Butterworth-Heinemann Publishers: Philadelphia, 115-124.
42. Ford, H., Trigwell, P. and Johnson, M. (1998) The nature of fatigue in multiple sclerosis, J Psychosom Res 45: 33-38.
43. Franklin, G.M., Heaton, R.K., Nelson, L.M., Filley, C.M. and Seibert, C. (1988) Correlation of neuropsychological and MRI findings in chronic / progressive multiple sclerosis, Neurology 38: 1826-1829.
44. Freal, J.E., Kraft, G.H. and Coryell, J.K. (1984) Symptomatic fatigue in multiple sclerosis, Arch Phys Med Rehabil 65: 135-138.
45. Ghaffar, O., Chamelian, L. and Feinstein, A. (2008) Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis, J Neurol 255: 406-412.
46. Ghaffar, O. and Feinstein, A. (2007) The neuropsychiatry of multiple sclerosis: a review of recent developments, Curr Opin Psychiatry 20: 278-285.
47. Gold, S.M. and Irwin, M.R. (2006) Depression and immunity: inflammation and depressive symptoms in multiple sclerosis, Neurol Clin 24: 507-519.
48. Golden Consensus Group (2005) The Goldman Consensus statement on depression in multiple sclerosis, Mult Scler 11: 328-337.
49. Griffiths, S.Y., Yamamoto, A., Boudreau, V.G., Ross, L.K., Kozora, E. and Thornton, A.E. (2005) Memory interference in multiple sclerosis, J Int Neuropsychol Soc 11: 737-746.
50. Haghikia, A., Ladage, K., Hinkerohe, D., Vollmar, P., Heupel, K., Dermietzel, R. et al. (2008) Implications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocytes, J Neurosci Res 86: 1781-1788.
51. Heesen, C., Mohr, D.C., Huitinga, I., ThenBergh, F., Gaab, J., Otte, C. et al. (2007) Stress regulation in multiple sclerosis - current issues and concepts, Mult Scler 13: 143-148.
52. Henry, J.D. and Beatty, W.W. (2006) Verbal fluency deficits in multiple sclerosis, Neuropsychologia 44: 1166-1174.
53. Henze, T., Rieckmann, P. and Toyka, K.V. (2006) Symptomatic treatment of multiple sclerosis multiple sclerosis therapy consensus group (MSTCG) of the German multiple sclerosis society, Eur Neurol 56: 78-105.
54. Hildebrandt, H., Hahn, H.K., Kraus, J.A., Schulte-Herbruggen, A., Schwarze, B. and Schwendemann, G. (2006) Memory performance in multiple sclerosis patients correlates with central brain atrophy, Mult Scler 12: 428-436.
55. Huber, S.J., Bornstein, R.A., Rammohan, K.W., Christy, J.A., Chakeres, D.W. and McGhee, R.B. (1992) Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis, J Neuropsychiatry Clin Neurosci 4: 152-158.
56. Huijbregts, S.C., Kalkers, N.F., de Sonneville, L.M., de Groot, V. and Polman, C.H. (2006) Cognitive impairment and decline in different MS subtypes, J Neurol Sci 245: 187-194.
57. Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferonbeta-1atherapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med 343: 898-904.
58. Janardhan, V. and Bakshi, R. (2002) Quality of life in patients with multiple sclerosis: the impact of fatigue and depression, J Neurol Sci 205: 51-58.
59. Janssens, A.C.J.W., Buljevac, D., van Doorn, P.A., van der Meche, F.G.A., Polman, C.H., Passchier, J. et al. (2006) Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study, Mult Scler 12: 794-801.
60. Janssens, A.C.J.W., van Doorn, P.A., de Boer, J.B., van der Meche, F.G.A., Passchier, J. and Hintzen, R.Q. (2003) Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners, Acta Neurol Scand 108: 389-395.
61. Jefferies, K. (2006) The neuropsychiatry of multiple sclerosis, Advan Psychiatr Treat 12: 214-220.
62. Jongen, P.J. (2006) Psychiatric onset of multiple sclerosis, J Neurol Sci 245: 59-62.
63. Jonsson, A., Dock, J. and Ravnborg, M.H. (1996) Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis, Acta Neurol Scand 93: 229-235.
64. Kahl, K.G., Kruse, N., Faller, H., Weiss, H. and Rieckmann, P. (2002) Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis, Psychoneuroendocrinology 27: 671-681.
65. Kato, T., Mizoguchi, Y., Monji, A., Horikawa, H., Suzuki, S.O., Seki, Y. et al. (2008) Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca(2+) regulation in vitro, J Neurochem 106: 815-825.
66. Kelley, K.W., Bluthe, R.M., Dantzer, R., Zhou, J.H., Shen, W.H., Johnson, R.W. et al. (2003) Cytokine-induced sickness behavior, Brain Behav Immun 17(Suppl. 1): S112-S118
67. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R. et al. (2003) The survey replication epidemiology of major depressive disorder results from the National Comorbidity Survey Replication, JAMA 289: 3095-3105
68. Korostil, M. and Feinstein, A. (2007) Anxiety disorders and their clinical correlates in multiple sclerosis patients, Mult Scler 13: 67-72.
69. Krupp, L.B., Alvarez, L.A., LaRocca, N.G. and Scheinberg, L.C. (1988) Fatigue in multiple sclerosis, Arch Neurol 45: 435-437.
70. Krupp, L.B., Christodoulou, C., Melville, P., Scherl, W.F., MacAllister, W.S. and Elkins, L.E. (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial, Neurology 63: 1579-1585.
71. Kumar, R. (2008) Approved and investigational uses of modafinil: an evidence-based review, Drugs 68: 1803-1839.
72. Larcombe, N.A. and Wilson, P.H. (1984) An evaluation of cognitive - behaviour therapy for depression in patients with multiple sclerosis, Br J Psychiatry 145: 366-371.
73. Lebrun, C. (2001) Therapeutic indications in symptomatic cognitive and psychopathological disorders in multiple sclerosis, Rev Neurol (Paris) 157: 1085-1090.
74. Leonard, B.E. (2001) The immune system, depression and the action of antidepressants, Prog Neuropsychopharmacol Biol Psychiatry 25: 767-780.
75. Lublin, F.D. and Reingold, S.C. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology 46: 907-911.
76. Martinelli, V. (2000) Trauma, stress and multiple sclerosis, Neurol Sci 21: S849-S852.
77. Mattingly, G., Baker, K., Zorumski, C.F. and Figiel, G.S. (1992) Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients, J Neuropsychiatry Clin Neurosci 4: 145-151.
78. McCabe, M.P. (2005) Mood and self-esteem of persons with multiple sclerosis following an exacerbation, J Psychosom Res 59: 161-166.
79. McDonald, I. and Compston, A. (2006) ‘The symptoms and signs of multiple sclerosis’, in Compston, A. et al. (eds) McAlpine's Multiple Sclerosis., 4th edition. Churchill Livingstone: Philadelphia, 321-322.
80. McIntosh-Michaelis, S.A., Roberts, M.H., Wilkinson, S.M., Diamond, I.D., McLellan, D.L., Martin, J.P. et al. (1991) The prevalence of cognitive impairment in a community survey of multiple sclerosis, Br J Clin Psychol 30: 333-348.
81. McNulty, K., Livneh, H. and Wilson, L.M. (2004) Perceived uncertainty, spiritual well-being and psychosocial adaptation in individuals with multiple sclerosis, Rehabil Psychol 9: 91-99.
82. Minden, S.L. and Schiffer, R.B. (1990) Affective disorders in multiple sclerosis: Review and recommendations for clinical research, Arch Neurol 47: 98-104.
83. Minden, S.L. (2000) Mood disorders in multiple sclerosis: diagnosis and treatment, J Neurovirol 6(Suppl. 2): S160-S167.
84. Mohr, D.C., Classen, C. and Barrera M. Jr. (2004) The relationship between social support, depression and treatment for depression in people with multiple sclerosis, Psychol Med 34: 533-541.
85. Mohr, D.C., Cox, D., Epstein, L. and Boudewyn, A. (2002) Teaching patients to self- inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications, J Behav Ther Exp Psychiatry 33: 39-47.
86. Mohr, D.C., Goodkin, D.E., Likosky, W., Gatto, N., Baumann, K.A. and Rudick, R.A. (1997) Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis, Arch Neurol 54: 531-533.
87. Mohr, D.C. and Goodkin, D.E. (1999) Treatment of depression in multiple sclerosis, Clin Psychol Sci Pract 6: 1-9.
88. Mohr, D.C., Hart, S.L. and Goldberg, A. (2003) Effects of treatment for depression on fatigue in multiple sclerosis, Psychosom Med 65: 542-547.
89. Moran, P.J. and Mohr, D.C. (2005) The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis, J Behav Med 28: 35-41.
90. O'Brien, A.R., Chiaravalloti, N., Goverover, Y. and Deluca, J. (2008) Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature, Arch Phys Med Rehabil 89: 761-769.
91. Panitch, H.S., Thisted, R.A., Smith, R.A., Wynn, D.R., Wymer, J.P., Achiron, A. et al. (2006) Randomized, controlled trial of dextromethorphan / quinidine for pseudobulbar affect in multiple sclerosis, Ann Neurol 59: 780-787.
92. Pantano, P., Mainero, C. and Caramia, F. (2006) Functional brain reorganization in multiple sclerosis: evidence from fMRI studies, J Neuroimaging 16: 104-114.
93. Patten, S.B., Beck, C.A., Williams, J.V., Barbui, C. and Metz, L.M. (2003) Major depression in multiple sclerosis: a population-based perspective, Neurology 61: 1524-1527.
94. Patten, S.B. and Metz, L.M. (2001) InterferonB-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial, Mult Scler 7: 243-248.
95. Patten, S.B., Svenson, L.W. and Metz, L.M. (2005) Psychotic disorders in MS: population-based evidence of an association, Neurology 65: 1123-1125.
96. Peraölaö, J., Suvisaari, J., Saarni, S.I., Kuoppasalmi, K., Isometsaö, E., Pirkola, S. et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population, Arch Gen Psychiatry 64: 19-28.
97. Pinkston, J.B., Kablinger, A. and Alekseeva, N. (2007) Multiple sclerosis and behavior, Int Rev Neurobiol 79: 323-339.
98. Plohmann, A.M., Kappos, L., Ammann, W., Thordai, A., Wittwer, A., Huber, S. et al. (1998) Computer assisted retraining of attentional impairments in patients with multiple sclerosis, J Neurol Neurosurg Psychiatry 64: 455-462.
99. Pollak, Y., Ovadia, H., Orion, E. and Yirmiya, R. (2003) The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments, J Neuroimmunol 137: 100-108.
100. Porcel, J., Rio, J., Sanchez-Betancourt, A., Arevalo, M.J., Tintore, M., Tellez, N. et al. (2006) Long-term emotional state of multiple sclerosis patients treated with interferon beta, Mult Scler 12: 802-807.
101. Price, R.K., North, C.S., Wessely, S. and Fraser, V.J. (1992) Estimating the prevalence of chronic fatigue syndrome and associated symptoms in the community, Public Health Rep 107: 514-522.
102. Puri, B.K., Bydder, G.M., Chaudhuri, K.R., Al Saffar, B.Y., Curati, W.L., White, S.J. et al. (2001) MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine, Neuroreport 12: 1821-1824.
103. Rabins, P.V., Brooks, B.R., O'Donell, P., Pearlson, G.D., Moberg, P., Jubelt, B. et al. (1986) Structural brain correlates of emotional disorder in multiple sclerosis, Brain 109: 585-597.
104. Rabins, P.V. (1990) ‘Euphoria in multiple sclerosis’. In Rao, S.M. (ed.) Neurobehavioural Aspects of Multiple Sclerosis. Oxford University Press: New York, 180-185.
105. Rammohan, K.W., Rosenberg, J.H., Lynn, D.J., Blumenfeld, A.M., Pollak, C.P. and Nagaraja, H.N. (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study, J Neurol Neurosurg Psychiatry 72: 179-183.
106. Rao, S.M., Leo, G.J., Bernadin, L. and Unverzagt, F. (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction, Neurology 41: 685-691.
107. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A. et al. (2001) Cytokine-associated emotional and cognitive disturbances in humans, Arch Gen Psychiatry 58: 445-452.
108. Reiss, J.P., Sam, D. and Sareen, J. (2006) Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans, J Clin Neurosci 13: 282-284.
109. Ritchie, K., Artero, S. and Touchon, J. (2001) Classification criteria for mild cognitive impairment: a population-based validation study, Neurology 56: 37-42.
110. Romani, A., Bergamaschi, R., Candeloro, E., Alfonsi, E., Callieco, R. and Cosi, V. (2004) Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment, Mult Scler 10: 462-468.
111. Ron, M.A. and Logsdail, S.J. (1989) Psychiatric morbidity in multiple sclerosis: a clinical and MRI study, Psychol Med 19: 887-895.
112. Sá, M.J. (2008) Psychological aspects of multiple sclerosis, Clin Neurol Neurosurg 110: 868-877.
113. Sadovnick, A.D. Eisen, K., Ebers, G.C. and Paty, D.W. (1991) Cause of death in patients attending multiple sclerosis clinics, Neurology 41: 1193-1196.
114. Sanfilipo, M.P., Benedict, R.H., Weinstock-Guttman, B. and Bakshi, R. (2006) Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis, Neurology 66: 685-692.
115. Schiffer, R.B. (1990) ‘Disturbances of affect’. In Rao, S.M. (ed.) Neurobehavioral Aspects of Multiple Sclerosis. Oxford University Press: New York, 186-195.
116. Schiffer, R.B., Herndon, R.M. and Rudick, R.A. (1985) Treatment of pathologic laughing and weeping with amitriptyline, N Engl J Med 312: 1480-1482.
117. Schiffer, R.B., Wineman, M. and Weitkamp, L.R. (1986) Association between bipolar affective disorder and multiple sclerosis, Am J Psychiatry 143: 94-105.
118. Schwid, S.R. and Murray, J.T. (2005) Treating fatigue in patients with MS: one step forward, one step back, Neurology 64: 1111-1112.
119. Scott, T.F., Nussbaum, P., McConnell, H. and Brill, P. (1995) Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale, Neurol Res 17: 421-422.
120. Seliger, G.M., Hornstein, A., Flax, J., Herbert, J. and Schroeder, K. (1992) Fluoxetine improves emotional incontinence, Brain Inj 6: 267-270.
121. Shackleton, B., Harrison, K. and Taylor, C. (2008) Dementia 2: early diagnosis and initial nursing care, Nurs Times 104: 26-27.
122. Shenal, B.V., Harrison, D.W. and Demaree, H.A. (2003) The neuropsychology of depression: a literature review and preliminary model, Neuropsychol Rev 13: 33-42.
123. Siegert, R.J. and Abernethy, D.A. (2005) Depression in multiple sclerosis: a review, J Neurol Neurosurg Psychiatry 76: 469-475.
124. Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L. et al. (2005) Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study, Neurology 64: 1139-1143.
125. Stenager, E.N., Stenager, E., Koch-Henriksen, N., Brønnum-Hansen, H., Hyllested, K., Jensen, K. et al. (1992) Suicide and multiple sclerosis: an epidemiological investigation, J Neurol Neurosurg Psychiatry 55: 542-545.
126. Storr, L.K., Sorensen, P.S. and Ravnborg, M. (2006) The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients, Mult Scler 12: 235-242.
127. Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O. et al. (2007) Pro- and antiinflammatory cytokine balance in major depression: effect of sertraline therapy, Clin Dev Immunol 2007: 76396.
128. Sweet, L.H., Rao, S.M., Primeau, M., Durgerian, S. and Cohen, R.A. (2006) Functional magnetic resonance imaging response to increased verbal working memory demands among patients with multiple sclerosis, Hum Brain Map 27: 28-36.
129. Taus, C., Giuliani, G., Pucci, E., D'Amico, R. and Solari, A. (2003) Amantadine for fatigue in multiple sclerosis, Cochrane Database Syst Rev 2003: CD002818.
130. Tellez, N., Rio, J., Tintore, M., Nos, C., Galan, I. and Montalban, X. (2006) Fatigue in multiple sclerosis persists over time: a longitudinal study, J Neurol 253: 1466-1470.
131. Thomas, P.W., Thomas, S., Hillier, C., Galvin, K., Baker, R. and The Cochrane Collaboration (2007) Psychological interventions for multiple sclerosis (review) The Cochrane Library. Vol 1. John Wiley & Sons: Chichester, 1-51.
132. Udaka, F., Yamao, S., Nagata, H., Nakamura, S. and Kameyama, M. (1984) Pathologic laughing and crying treated with levodopa, Arch Neurol 41: 1095-1096.
133. van Kessel, K., Moss-Morris, R., Willoughby, E., Chalder, T., Johnson, M.H. and Robinson, E. (2008) A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue, Psychosom Med 70: 205-213.
134. Vercoulen, J.H.M.M., Hommes, O.R., Swanink, C.M.A., Jongen, P.J., Fennis, J.F., Galama, J.M. et al. (1996) The measurement of fatigue in patients with multiple sclerosis: a multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects, Arch Clin Neurol 53: 642-649.
135. Wei, T. and Lightman, S.L. (1997) The neuroendocrine axis in patients with multiple sclerosis, Brain 120: 1067-1076.
136. Williams, R.M., Turner, A.P., Hatzakis, M., Chu, S., Rodriquez, A.A., Bowen, J.D. et al. (2004) Social support among veterans with multiple sclerosis, Rehabil Psychol 49: 106-113.
137. Young, C.R., Weiss, E.L., Bowers Jr, M.B. and Mazure, C.M. (1997) The differential diagnosis of multiple sclerosis and bipolar disorder, J Clin Psychiatry 58: 123.
138. Zéphir, H., de Seze, J., Dujardin, K., Dubois, G., Cabaret, M., Bouillaguet, S. et al. (2005) One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis, Mult Scler 11: 360-363.
139. Zhu, J., Wei, X., Feng, X., Song, J., Hu, Y. and Xu, J. (2008) Repeated administration of mirtazapine inhibits development of hyperalgesia / allodynia and activation of NF-kappaB in a rat model of neuropathic pain, Neurosci Lett 433: 33-37.
140. Zorzon, M., deMasi, R., Nasuelli, D., Ukmar, M., Mucelli, R.P., Cazzato, G. et al. (2001) Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects, J Neurol 248: 416-421.